Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages

Biophysical Chemistry

Volumn 217, Issue , 2016, Pages 20-31

  da Gama Bitencourt, José Jardes ^a   Pazin, Wallance Moreira ^a   Ito, Amando Siuiti ^a   Barioni, Marina Berardi ^a   de Paula Pinto, Carolline ^a   Santos, Maria Aparecida dos ^a   Guimarães, Thales Henrique Santos ^a   Santos, Márcia Regina Machado dos ^a   Valduga, Claudete Justina ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemolytic potential; Leishmaniasis; Lipid nanoparticles; Miltefosine

Indexed keywords

AMPHOTERICIN B; CHOLESTEROL; LIPID NANOPARTICLE; MILTEFOSINE; NANOPARTICLE; PHOSPHOLIPID; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; DRUG CARRIER; LIPID; PHOSPHORYLCHOLINE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; FLUORESCENCE CORRELATION SPECTROSCOPY; GASTROINTESTINAL TOXICITY; HEMOLYSIS; HUMAN; HUMAN CELL; LEISHMANIA CHAGASI; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROMASTIGOTE; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL DEATH; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; GASTROINTESTINAL DISEASES; PATHOLOGY; RAW 264.7 CELL LINE;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL DEATH; CELLS, CULTURED; DRUG CARRIERS; DRUG STABILITY; ERYTHROCYTES; GASTROINTESTINAL DISEASES; HEMOLYSIS; HUMANS; LIPIDS; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; PHOSPHORYLCHOLINE; RAW 264.7 CELLS;

EID: 84980340039     PISSN: 03014622     EISSN: 18734200     Source Type: Journal    
DOI: 10.1016/j.bpc.2016.07.005     Document Type: Article

References (60)

1. [1] WHO, Leishmaniasis. in http://www.who.int/leishmaniasis/en/ (acessed in july 27th, 2014).
2. [2] Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M., WHO Leishmaniasis Control Team, Leishmaniasis worldwide and global estimates of its incidence. PLoS One, 7, 2012, e35671.
3. [3] Pham, T.T.H., Loiseau, P.M., Barratt, G., Strategies for the design of orally bioavailable antileishmanial treatments. Int. J. Pharm. 454 (2013), 539–552.
4. [4] Bhattacharya, S.K., Sinha, P.K., Sundar, S., et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196 (2007), 591–598.
5. [5] Seifert, K., Matu, S., Javier Perez-Victoria, F., Castanys, S., Gamarro, F., Croft, S.L., Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine(miltefosine). Int. J. Antimicrob. Agents 22 (2003), 380–387.
6. [6] Fernández, O.L., Toro, Y.D., Ovalle, C., Valderrama, L., Muvdi, S., Rodríguez, I., Gomez, M.A., Saravia, N.G., Miltefosine and Antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS Negl. Trop. Dis., 8, 2014, e2871.
7. [7] Dorlo, T.P., Balasegaram, M., Beijnen, J.H., de Vries, P.J., Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J. Antimicrob. Chemother. 67:11 (2012), 2576–2597.
8. [8] Croft, S.L., Seifert, K., Duchêne, M., Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 126 (2003), 165–172.
9. [9] Azzouz, S., Maache, M., Garcia, R.G., Osuna, A., Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin. Pharmacol. Toxicol. 96 (2005), 60–65.
10. [10] Papazafiri, P., Avlonitis, N., Angelou, P., Calogeropoulou, T., Koufaki, M., Scoulica, E., Fragiadaki, I., Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives. Cancer Chemother. Pharmacol. 56 (2005), 261–270.
11. [11] Fiegl, M., Lindner, L.H., Juergens, M., Eibl, H., Hiddemann, W., Braess, J., Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother. Pharmacol. 62 (2008), 321–329.
12. [12] Barioni, M.B., Ramos, A.P., Zaniquelli, M.E., Acuña, A.U., Ito, A.S., Miltefosine and BODIPY-labeled alkylphosphocholine with leishmanicidal activity: aggregation properties and interaction with model membranes. Biophys. Chem. 196 (2015), 92–99.
13. [13] Heerklotz, H., Interactions of surfactants with lipid membranes. Q. Rev. Biophys. 41 (2008), 205–264.
14. [14] Jha, T.K., Sundar, S., Thakur, C.P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., Berman, J., Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341 (1999), 1795–1800.
15. [15] Wieder, T., Reutter, W., Orfanos, C.E., Geilen, C.C., Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res. 38 (1999), 249–259.
16. [16] Escroffre, J.M., Bellard, E., Faurie, C., Sébai, S.C., Golzio, M., Teissié, J., Rols, M.P., Membrane disorder and phospholipid scrambling in electropermeabilized and viable cells. Biochim. Biophys. Acta 1838 (2014), 1701–1709.
17. [17] Munoz, C., Alzoubi, K., Janin, J., Abed, M., Lang, F., Effect of miltefosine on erythrocytes. Toxicol. in Vitro 27 (2013), 1913–1919.
18. [18] Chowdhary, S.J., Chowdhary, A., Kashaw, S., Macrophage targeting: a strategy for leishmaniasis specific delivery. Int J Pharm Pharm Sci 8:2 (2016), 16–26.
19. [19] Kaufmann-Kolle, P., Drevs, J., Berger, M.R., Kötting, J., Marschner, N., Unger, C., Eibl, H., Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol. 34 (1994), 393–398.
20. [20] Perkins, W.R., Dause, R.B., Li, X., Franklin, J.C., Cabral-Lilly, D.J., Zha, Y., Dank, E.H., Mayhew, E., Janoff, A.S., Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta 1327 (1997), 61–68.
21. [21] Zhukova, M.V., Romanenko, O.V., Nikolaevich, V.A., Kisel, M.A., Hemolytic properties of miltefosine in liposomes of various lipid compositions. Pharm. Chem. J. 44 (2010), 507–509.
22. [22] Das, S., Khan, W., Mohsin, S., Kumar, N., Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation. Polym. Adv. Technol. 22 (2010), 172–179.
23. [23] Eissa, M.M., El-Moslemany, R.M., Ramadan, A.A., Amer, E.I., El-Azzouni, M.Z., El-Khordagui, L.K., Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study. PLoS One, 10(11), 2015, e0141788.
24. [24] Rael, L.T., Thomas, G.W., Craun, M.L., Curtis, C.G., Bar-Or, R., Bar-Or, D., Lipid peroxidation and the thiobarbituric acid assay: standardization of the assay when using saturated and unsaturated fatty acids. J. Biochem. Mol. Biol. 37 (2004), 749–752.
25. [25] Widmer, F., Wright, L.C., Obando, D., Handke, R., Ganendren, R., Ellis, D.H., Sorrell, T.C., Hexadecyl phosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 50 (2006), 414–421.
26. [26] Anazetti, M.C., Melo, P.S., Duran, N., Haun, M., Comparative cytotoxicity of dimethylamide-crotonin in the promyelocytic leukemia cell line (HL 60) and human peripheral blood mononuclear cells. Toxicology 188 (2003), 261–274.
27. [27] Vistica, D.T., Skehan, P., Scudiero, D., Monks, A., Pittman, A., Boyd, M.R., Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 51 (1991), 2515–2520.
28. [28] Carmo, E.V., Katz, S., Barbiéri, C.L., Neutrophils reduce the parasite burden in Leishmania (Leishmania) amazonensis-infected macrophages. PLoS One, 5(11), Nov 3 2010, e13815.
29. [29] Pouton, C.W., Porter, C.J., Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 60 (2008), 625–663.
30. [30] Kawato, S., Kinosita, K. Jr., Ikegami, A., Effect of cholesterol on the molecular motion in the hydrocarbon region of lecithin bilayers studied by nanosecond fluorescence techniques. Biochemistry 14 (1978), 5026–5031.
31. [31] Ito, A.S., Rodrigues, A.P., Pazin, W.M., Barioni, M.B., Fluorescence depolarization analysis of thermal phase transition in DPPC and DMPG aqueous dispersions. J. Lumin. 158 (2015), 153–159.
32. [32] Muller-Goymann, C.C., Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur. J. Pharm. Biopharm. 58 (2004), 343–356.
33. [33] Castro, B.M., Fedorov, A., Hornillos, V., Delgado, J., Acuña, A.U., Mollinedo, F., Prieto, M., Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids. J. Phys. Chem. B 117 (2013), 7929–7940.
34. [34] Alonso, L., Alonso, A., Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data. Biochim. Biophys. Acta 1858 (2016), 1160–1164.
35. [35] Dorlo, T.P., Huitema, A.D., Beijnen, J.H., de Vries, P.J., Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob. Agents Chemother. 56:7 (2012), 3864–3872.
36. [36] Dorlo, T.P., Rijal, S., Ostyn, B., de Vries, P.J., Singh, R., Bhattarai, N., Uranw, S., Dujardin, J.C., Boelaert, M., Beijnen, J.H., Huitema, A.D., Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J. Infect. Dis. 210:1 (2014), 146–153.
37. [37] Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N.R., Dorlo, T.P., Beijnen, J.H., Vanaerschot, M., Decuypere, S., Dhakal, S.S., Das, M.L., Karki, P., Singh, R., Boelaert, M., Dujardin, J.C., Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin. Infect. Dis. 56 (2013), 1530–1538.
38. [38] Dorlo, T.P., van Thiel, P.P., Huitema, A.D., Keizer, R.J., de Vries, H.J., Beijnen, J.H., de Vries, P.J., Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 52 (2008), 2855–2860.
39. [39] Aulner, N., Danckaert, A., Rouault-Hardoin, E., Desrivot, J., Helynck, O., Commere, P.-H., Munier-Lehmann, H., Späth, G.F., Shorte, S.L., Milon, G., Prina, E., High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery. PLoS Negl. Trop. Dis., 7(4), April 2013, e2154.
40. [40] Papagiannaros, A., Bories, C., Demetzos, C., Loiseau, P.M., Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother. 59 (2005), 545–550.
41. [41] Silva, A.E., Barratt, G., Chéron, M., Egito, E.S.T., Development of oil-in-water microemulsions for the oral delivery of amphotericin B. Int. J. Pharm. 454 (2013), 641–648.
42. [42] Borborema, S.E., Schwendener, R.A., Osso, J.A. Jr., de Andrade, H.F. Jr., do Nascimento, N., Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int. J. Antimicrob. Agents 38 (2011), 341–347.
43. [43] Asthana, S., Gupta, P.K., Chaurasia, M., Dube, A., Chourasia, M.K., Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos. Expert Opin. Drug Deliv. 10 (2013), 1633–1651.
44. [44] Carneiro, G., Aguiar, M.G., Fernandes, A.P., Ferreira, L.A., Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert Opin. Drug Deliv. 9 (2012), 1083–1097.
45. [45] Ejazi, S.A., Ali, N., Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Rev. Anti-Infect. Ther. 11 (2013), 79–98.
46. [46] Khalil, N.M., de Mattos, A.C., Carraro, T.C., Ludwig, D.B., Mainardes, R.M., Nanotechnological strategies for the treatment of neglected diseases. Curr. Pharm. Des. 19 (2013), 7316–7329.
47. [47] Momeni, A., Rasoolian, M., Momeni, A., Navaei, A., Emami, S., Shaker, Z., Mohebali, M., Khoshdel, A., Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. J. Liposome Res. 23 (2013), 134–144.
48. [48] Moreno, E., Schwartz, J., Fernández, C., Sanmartín, C., Nguewa, P., Irache, J.M., Espuelas, S., Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis. Expert Opin. Drug Deliv. 11 (2014), 579–597.
49. [49] Pham, T.T.H., Gueutin, C., Cheron, M., Abreu, S., Chaminade, P., Loiseau, P.M., Barratt, G., Development of antileishmanial lipid nanocomplexes. Biochimie(14), 2014, 00150–00153 (pii: S0300-9084).
50. [50] Romero, E.L., Morilla, M.J., Drug delivery systems against leishmaniasis? Still an open question. Expert Opin. Drug Deliv. 5 (2008), 805–823.
51. [51] Singh, N., Mishra, B.B., Bajpai, S., Singh, R.K., Tiwari, V.K., Natural product based leads to fight against leishmaniasis. Bioorg. Med. Chem. 22 (2014), 18–45.
52. [52] Sundar, S., Singh, A., Singh, O.P., Strategies to overcome antileishmanial drugs unresponsiveness. J. Trop. Med., 2014, 2014, 646932.
53. [53] Fatouros, D.G., Bergenstahl, B., Mullertz, A., Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur. J. Pharm. Sci. 31 (2007), 85–94.
54. [54] Fatouros, D.G., Mullertz, A., Using in vitro dynamic lipolysis modeling as a tool for exploring IVIVC relationships for oral lipid-based formulations. Hauss, D.J., (eds.) Oral Lipid-based Formulations: Enhancing the Bioavailability of Poorly Water Soluble Drugs, 2007, Informa Healthcare, Inc., New York, 257–271.
55. [55] van Aken, G.A., Bomhof, E., Zoet, F.D., Verbeek, M., Oosterveld, A., Differences in in vitro gastric behaviour between homogenized milk and emulsions stabilised by Tween 80, whey protein, or whey protein and caseinate. Food Hydrocoll. 25 (2011), 781–788.
56. [56] Nerurkar, M.M., Burton, P.S., Borchardt, R.T., The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13 (1996), 528–534.
57. [57] Koga, K., Murakami, M., Kawashima, S., Modification of ceftibuten transport by changes in lipid fluidity caused by fatty acid glycerol esters. Biol. Pharm. Bull. 22 (1999), 103–106.
58. [58] Rege, B.D., Kao, J.P., Polli, J.E., Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16 (2002), 237–246.
59. [59] Strickley, R.G., Currently marketed oral lipid-based dosage forms: drugs products and excipients. Hauss, D.J., (eds.) Oral Lipid-based Formulations: Enhancing the Bioavailability of Poorly Water Soluble Drugs, 2007, Informa Healthcare, Inc., New York, 1–31.
60. [60] Tovani, C.B., Souza, J.F.V., Cavallini, T.S., Demets, G.J.-F., Ito, A.S., Barioni, M.B., Pazin, W.M., Zaniquelli, M.E.D., Comparison between Cucurbiturils and β-cyclodextrin interactions with cholesterol molecules present in Langmuir monolayers used as a biomembrane model. Colloids Surf. B: Biointerfaces 111 (2013), 398–406.